Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...

Sox9, a master regulator of cartilage formation, switches its target genes dynamically during embryonic limb development ...

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

Atrium Therapeutics, Inc. (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan" ...

University of California San Diego researchers have developed a new tool for understanding and modifying any microbiome, ...

The global immuno-oncology drugs market is expanding rapidly due to rising cancer prevalence and sustained clinical benefits.

Eli Lilly LLY announced a definitive agreement to acquire Kelonia Therapeutics in a deal valued at up to $7 billion, ...

Meet us at BIO Convention in San Diego from 22 to 25 June, 2026on the French PavillonFocus on French HealthTech’s ecosystem :Panorama France ...

Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...